Fate Therapeutics (NASDAQ:FATE – Get Free Report) and TuHURA Biosciences (NASDAQ:HURA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Profitability
This table compares Fate Therapeutics and TuHURA Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -2,187.11% | -51.28% | -36.37% |
| TuHURA Biosciences | N/A | -196.68% | -123.41% |
Volatility and Risk
Fate Therapeutics has a beta of 2.24, indicating that its stock price is 124% more volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 5 | 3 | 0 | 2.22 |
| TuHURA Biosciences | 1 | 0 | 2 | 1 | 2.75 |
Fate Therapeutics currently has a consensus price target of $3.92, suggesting a potential upside of 141.77%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 542.86%. Given TuHURA Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Fate Therapeutics.
Insider and Institutional Ownership
97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Fate Therapeutics and TuHURA Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $13.63 million | 13.71 | -$186.26 million | ($1.32) | -1.23 |
| TuHURA Biosciences | N/A | N/A | -$21.68 million | ($0.50) | -2.80 |
TuHURA Biosciences has lower revenue, but higher earnings than Fate Therapeutics. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Fate Therapeutics beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About TuHURA Biosciences
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
